Open AccessP1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM‐CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.
Author(s) -
Ladetto M.,
Tavarozzi R.,
Evangelista A.,
Zanni M.,
Tucci A.,
Anastasia A.,
Botto B.,
Boccomini C.,
Bolis S.,
Volpetti S.,
Zilioli V. R.,
Puccini B.,
Arcari A.,
Pavone V.,
Gaidano G.,
Corradini P.,
Tani M.,
Ferrero S.,
Cavallo F.,
Milone G.,
Ghiggi C.,
Pinto A.,
Pastore D.,
Ferreri A. J.,
Latte G.,
Patti C.,
Re F.,
Arcaini L.,
Benedetti F.,
Usai S. V.,
Luminari S.,
Mannina D.,
Pulsoni A.,
Stelitano C.,
Pennese E.,
Pietrantuono G.,
Gherlinzoni F.,
Pomponi F.,
Olivieri A.,
Perrone T.,
Rota Scalabrini D.,
Califano C.,
Falini B.,
Ciccone G.,
Vitolo U.
Publication year - 2022
Publication title -
hemasphere
Language(s) - Italian
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847444.51476.b0
Subject(s) - medicine , autologous stem cell transplantation , chemoimmunotherapy , follicular lymphoma , ibritumomab tiuxetan , population , radioimmunotherapy , oncology , clinical endpoint , progression free survival , phases of clinical research , surgery , rituximab , clinical trial , transplantation , chemotherapy , lymphoma , immunology , antibody , monoclonal antibody , environmental health